Genentech has taken the unusual step of publishing negative safety data from its preclinical LRRK2 program, and The Michael J. Fox Foundation is pulling stakeholders together to determine the clinical implications.
Swiss researchers have bypassed the need to create huge compound libraries by designing a dual-display system that detects high affinity pairs from two sub-libraries of molecules.
While early-stage financing for European biotechs is still a far cry from that in the U.S., the 2014 numbers suggest some countries are getting better at commercializing their academic discoveries.
TRANSLATION IN BRIEF
A genetic marker could predict hearing loss in children receiving chemotherapy.
POLQ is the culprit behind cancers caused by some faulty DNA repair systems.
Induced hepatocyte-like cells create a screening model for malaria
THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.
This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.
This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.